FARON PHARMACEUTICALS OY ("Faron" or the "Company")
Faron's Annual Report 2020 published
Company announcement,
For more information please contact:
Dr
investor.relations@faron.com
Phone: +44 207 213 0880
Phone: +44 207 886 2500
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations
Phone: +1 212 362 1200
E-mail: faron@sternir.com
About
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the
Attachment:
Faron's Annual Report 2020.pdf
https://news.cision.com/faron-pharmaceuticals-oy/r/faron-s-annual-report-2020-published,c3313813
https://mb.cision.com/Main/19398/3313813/1392384.pdf
(c) 2021 Cision. All rights reserved., source
